Diagnosis of primary and recurrent bladder cancer is one of the most difficult problems in urology and cytology. Bladder cancer is a chronic illness, and the patients need continuous surveillance for early detection of recurrence and progression. Fluorescence in situ hybridization (FISH) is a rapid and powerful technique to detect cytogenetic abnormalities in malignant cells independent of their functional status. UroVysion multicolor FISH is a highly sensitive and specific method for the detection of bladder cancer in voided urine specimens. UroVysion detects chromosomal abnormalities associated with the development and recurrence of bladder cancer via fluorescence in situ hybridization (FISH): aneuploidy (>2 copies) for chromosomes 3, 7 and 17, and loss of the 9p21 locus (located on the p16 gene). It is an FDA approved diagnostic assay.
Methodology: Fluorescent in Situ Hybridization (FISH) Analysis
Purpose: Confirmation of Clinical Diagnosis/Monitor During Treatment
Test Requisition: Cancer Requisition
Turn-around-time: 2-5 days
1. Bubendorf L, Grilli B, Sauter G, Mihatsch M,Gasser T, Dalquen P. (2011) “Multiprobe FISH for Enhanced Detection of Bladder Cancer in Voided Urine Specimens and Bladder Washings”. Am J Clin Pathol 116:79-86.